Study guide

17.1 Epilepsy & Acute Seizures

MRCP UK

Track your progress as you read

Finished sections get a check mark.

1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy

1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique

2 Clinical Sciences: Cellular, Genetic & Molecular Medicine

2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders

3 Clinical Sciences: Anatomy, Physiology & Immunology

3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions

4 Clinical Sciences: Statistics, Epidemiology & Trial Design

4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification

5 Clinical Pharmacology, Therapeutics & Toxicology

5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols

6 Cardiology: Coronary Artery Disease & Heart Failure

6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation

7 Cardiology: Arrhythmias, Valvular & Pericardial Disease

7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases

8 Respiratory Medicine: Airway & Parenchymal Lung Disease

8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis

9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders

9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing

10 Gastroenterology: Luminal Gastrointestinal Disease

10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia

11 Gastroenterology: Liver, Biliary & Pancreatic Disease

11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis

12 Endocrinology & Diabetes: Diabetes & Thyroid

12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules

13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium

13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease

14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease

14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases

15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance

15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis

16 Neurology: Cerebrovascular, Headache & Demyelinating Disease

16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases

17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease

17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders

18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease

18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies

19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy

19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease

20 Infectious Diseases & Tropical Medicine

20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites

21 Haematology: Anaemias & Red Cell Disorders

21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease

22 Haematology: Malignancy, Coagulation & Transfusion Medicine

22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions

23 Psychiatry in General Medicine

23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law

24 Geriatric Medicine

24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers

25 Dermatology

25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy

26 Oncology & Palliative Medicine

26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control

27 Medical Ophthalmology

27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease

17.1 Epilepsy & Acute Seizures

Key Takeaways Explain This Topic AI

Under the ILAE 2017 classification, seizures are categorized by onset into focal (aware vs impaired awareness; motor vs non-motor; focal to bilateral tonic-clonic), generalised (tonic-clonic, absence, myoclonic, atonic), and unknown onset.

NICE guidelines recommend lamotrigine or levetiracetam as first-line monotherapy for focal seizures; sodium valproate is first-line for generalised tonic-clonic and myoclonic seizures in males and post-menopausal females, but is strictly contraindicated in females of childbearing potential unless the Valproate Safety Measures / Pregnancy Prevention Programme are met.

Absence seizures are treated first-line with ethosuximide (T-type calcium channel blocker) or sodium valproate; carbamazepine, phenytoin, and vigabatrin paradoxically exacerbate absence seizures and myoclonus and must be avoided.

Status epilepticus (convulsive seizures >=5 minutes) requires immediate protocolized management: Step 1 (0–10 min) with IV lorazepam 4 mg (or buccal midazolam 10 mg / rectal diazepam 10 mg); Step 2 (10–30 min) with IV levetiracetam (60 mg/kg), IV sodium valproate (40 mg/kg), or IV phenytoin/fosphenytoin (20 mg/kg); Step 3 (30–60 min) with general anaesthesia in ITU.

Under UK DVLA regulations, a single unprovoked seizure requires a 6-month driving cessation for Group 1 licenses, whereas established epilepsy requires 12 months of continuous seizure freedom before license reinstatement.

Last updated: September 2026

Epilepsy and acute seizures form one of the highest-yield topics in MRCP(UK) Part 1. Candidates must master clinical seizure classification, evidence-based antiepileptic drug (AED) selection according to NICE guidelines, unique AED pharmacokinetic and toxicological profiles, emergency status epilepticus management, and statutory UK DVLA driving regulations.

1. ILAE 2017 Seizure Classification

The International League Against Epilepsy (ILAE 2017) classifies seizures based on three key levels: type of onset (focal, generalised, or unknown), awareness during the seizure (for focal seizures), and motor versus non-motor manifestations .

Focal Seizures

Focal seizures originate within neuronal networks limited to one cerebral hemisphere:

Focal Aware Seizures (formerly Simple Partial): Consciousness and awareness remain fully intact throughout the event. Manifestations depend on the cortical locus:

Motor onset: Jacksonian march (clonic jerking spreading progressively along the motor strip homunculus), versive head/eye turning, vocalisation, or unilateral posturing.

Sensory onset: Parietal lobe origin producing contralateral paraesthesias, flashing lights (occipital), or olfactory/gustatory hallucinations (uncus).

Autonomic onset: Temporal lobe origin characteristically presenting with an epigastric rising sensation, flushing, diaphoresis, or pupillary changes.

Cognitive / Emotional onset: Temporal or limbic origin producing déjà vu, jamais vu, dreamy states, depersonalisation, micro/macropsia, or unprovoked sudden fear/panic.

Focal Impaired Awareness Seizures (formerly Complex Partial): Consciousness or awareness is impaired or lost at any point during the seizure. Patients typically exhibit behavioral arrest, vacant staring, and automatisms (involuntary, repetitive, semi-purposeful motor behaviours such as lip smacking, chewing, swallowing, or manual fumbling), followed by post-ictal confusion and amnesia.

Focal to Bilateral Tonic-Clonic (formerly Secondary Generalisation): Seizure activity initiates focally (often with a recognizable aura) before propagating across both cerebral hemispheres, terminating in a generalised tonic-clonic seizure.

Generalised Seizures

Generalised seizures originate simultaneously within bilaterally distributed cerebral networks from onset, with immediate impairment of consciousness:

Generalised Tonic-Clonic (GTC): Sudden loss of consciousness, tonic phase (sustained axial and limb stiffening, ictal cry from forced expiration against closed vocal cords, respiratory arrest, cyanosis), followed by clonic phase (synchronous rhythmic jerking of all limbs, tongue biting— lateral border laceration is highly specific for epileptic seizure —and urinary incontinence). Followed by post-ictal flaccidity, stertorous breathing, deep sleep, headache, myalgias, and transient focal weakness ( Todd's paresis ).

Absence Seizures (Petit Mal): Sudden, brief (5–15 seconds) behavioral arrest and unresponsiveness with immediate recovery, lacking post-ictal confusion. Classic EEG finding is synchronous 3 Hz generalized spike-and-wave discharges , frequently provoked by hyperventilation.

Myoclonic Seizures: Sudden, brief (<100 milliseconds), shock-like involuntary muscle contractions without loss of consciousness. Prominent in Juvenile Myoclonic Epilepsy (JME) .

Atonic Seizures ("Drop Attacks"): Sudden loss of postural muscle tone lasting <2 seconds, precipitating traumatic falls, typically seen in severe epileptic encephalopathies (e.g. Lennox-Gastaut syndrome).

Juvenile Myoclonic Epilepsy (JME / Janz Syndrome)

Idiopathic generalised epilepsy accounting for ~10% of all epilepsies, typically presenting between ages 12 and 18.

Characterized by the clinical triad of: 1. Early morning bilateral myoclonic jerks (characteristically causing patients to drop cups, toothbrushes, or cutlery shortly after waking); 2. Generalised tonic-clonic seizures ; 3. Typical absence seizures (in ~30%).

Triggered by sleep deprivation, fatigue, alcohol consumption, and stroboscopic photic stimulation.

EEG reveals generalized 4–6 Hz polyspike-and-wave discharges on a normal background.

2. NICE Guideline-Directed Antiepileptic Drug (AED) Selection

NICE guidelines (NG217) provide clear hierarchies for initial AED monotherapy based on confirmed seizure semiology:

Seizure Semiology First-Line Monotherapy Alternative / Second-Line Add-On Therapies Exacerbating Drugs (STRICTLY CONTRAINDICATED)

Focal Seizures (± progression to bilateral tonic-clonic) Lamotrigine OR Levetiracetam Carbamazepine, Lacosamide, Zonisamide, Sodium valproate (males) -

Generalised Tonic-Clonic Sodium valproate (first-line in males & post-menopausal females); Levetiracetam or Lamotrigine (females of childbearing potential) Topiramate, Clobazam, Brivaracetam Carbamazepine, Phenytoin, Vigabatrin (may worsen unrecognized myoclonic components)

Absence Seizures Ethosuximide OR Sodium valproate (males) Lamotrigine Carbamazepine, Phenytoin, Gabapentin, Pregabalin, Vigabatrin, Tiagabine (paradoxically provoke absence status!)

Myoclonic Seizures (including JME) Levetiracetam OR Sodium valproate (males) Topiramate, Clobazam, Brivaracetam Carbamazepine, Phenytoin, Lamotrigine (can paradoxically worsen myoclonus), Vigabatrin, Gabapentin

Atonic / Tonic Seizures Sodium valproate (males), Lamotrigine Topiramate, Rufinamide, Clobazam Carbamazepine, Phenytoin

Valproate Safety Measures & Pregnancy Prevention Programme

Teratogenicity Profile: Exposure to sodium valproate during pregnancy carries an exceptionally high risk of major congenital malformations in ~10% of infants (neural tube defects such as spina bifida [10-fold increase], congenital heart defects, cleft palate, and hypospadias) and neurodevelopmental disorders in 30–40% (autism spectrum disorders, ADHD, cognitive impairment, and reduced verbal IQ).

Regulatory Mandate (MHRA & NICE): Valproate is strictly contraindicated in girls and women of childbearing potential unless no other antiepileptic is effective, and the patient is enrolled in the mandatory Valproate Pregnancy Prevention Programme (Prevent) , utilizing highly effective long-acting reversible contraception (LARC) and signing an annual risk acknowledgement form. From 31 January 2024 the MHRA extended the restriction to men: valproate must not be started in any new patient under 55 years, male or female, unless two specialists independently agree and document that there is no other effective or tolerated treatment, or that there are compelling reasons why the reproductive risks do not apply. The measure was prompted by evidence of impaired male fertility as well as the established teratogenic risk. The MHRA subsequently clarified that a two-clinician annual review is not required for men already established on valproate; the two-specialist requirement applies to initiation in under-55s.

3. High-Yield Antiepileptic Drug Pharmacology & Toxicities

Antiepileptic Drug Mechanism of Action Characteristic Pharmacokinetics High-Yield Adverse Effects & Monitoring Requirements

Carbamazepine Voltage-gated sodium channel blocker Potent hepatic CYP450 inducer; undergoes auto-induction (half-life shortens over 2–4 weeks) - SIADH / Dilutional hyponatraemia (in up to 20%); - Leukopenia and agranulocytosis / aplastic anaemia (monitor FBC); - Stevens-Johnson syndrome (SJS) / TEN : strongly linked to HLA-B*1502 allele in Han Chinese and Southeast Asians (mandatory pre-treatment screening); - Ataxia, diplopia, nystagmus

Lamotrigine Voltage-gated sodium channel blocker; inhibits glutamate release Glucuronidated in liver; no CYP induction. Clearance doubled by oestrogen-containing OCPs and pregnancy - Severe cutaneous rash / SJS / TEN : requires slow, stepwise dose titration ("start low, go slow"); - Pharmacokinetic interaction with Valproate : Valproate inhibits lamotrigine glucuronidation (doubles lamotrigine half-life), requiring a 50% dose reduction of lamotrigine

Levetiracetam Binds Synaptic Vesicle Protein 2A (SV2A) , inhibiting presynaptic exocytosis Predominantly renally cleared (~66% unchanged); minimal CYP metabolism and negligible drug interactions - Behavioural and psychiatric adverse effects : irritability, agitation, anxiety, depression, aggressive behaviour, psychosis; - Somnolence, asthenia, dizziness

Sodium Valproate Blocks T-type Ca²⁺ and Na⁺ channels; enhances central GABA levels Potent hepatic CYP450 enzyme inhibitor ; displaces drugs from albumin - Teratogenicity (spina bifida, neurodevelopmental delay); - Weight gain, appetite stimulation; - Transient alopecia (hair frequently regrows curly); - Fine postural tremor (dose-dependent); - Hepatotoxicity (idiosyncratic, especially in POLG mutations); - Acute pancreatitis, hyperammonaemic encephalopathy, thrombocytopenia

Phenytoin Voltage-gated sodium channel blocker Zero-order (saturation) kinetics at therapeutic levels (10–20 mg/L / 40–80 μmol/L); small dose rise causes exponential level surge. Potent CYP inducer - Acute toxicity: Cerebellar-vestibular signs ( horizontal nystagmus [earliest sign], ataxia, dysmetria, slurred speech), confusion, coma; - Chronic toxicity: Gingival hypertrophy , coarsened facial features, hirsutism, peripheral neuropathy, Dupuytren's contracture, osteomalacia, megaloblastic anaemia (folate deficiency), lymphadenopathy

Topiramate Blocks Na⁺ channels, potentiates GABA, inhibits AMPA/kainate, weak carbonic anhydrase inhibitor Renal excretion (~70% unchanged) - Cognitive slowing ("dopamax"), word-finding difficulty, psychomotor slowing; - Weight loss / anorexia; - Nephrolithiasis (calcium phosphate stones via carbonic anhydrase inhibition and hypocitraturia); - Acute angle-closure glaucoma and acute myopia (ciliary body effusion); - Teratogenic (oral clefts)

Ethosuximide Blocks low-threshold T-type voltage-gated calcium channels in thalamocortical neurons Hepatic metabolism via CYP3A4 First-line monotherapy for absence seizures; adverse effects include nausea, vomiting, anorexia, insomnia, headache, and rarely blood dyscrasias / SJS

4. Emergency Management Protocol for Status Epilepticus

Status epilepticus is a medical emergency defined operationally as continuous convulsive seizure activity lasting >= 5 minutes , or two or more distinct seizures without full recovery of consciousness between episodes (T1 threshold = 5 min, initiating emergency therapy; T2 threshold = 30 min, beyond which long-term neuronal necrosis and excitotoxic damage occur). Convulsive Seizure >= 5 Minutes (Status Epilepticus)

  • │
  • ├── STEP 1 (0–10 min): Immediate Bedside Stabilisation & First-Line Benzodiazepine
  • │ ├── High-flow 15 L/min O2 via non-rebreather mask; maintain patent airway
  • │ ├── Check capillary blood glucose (give IV 20% glucose + thiamine if hypoglycaemic)
  • │ └── IV access: IV Lorazepam 4 mg bolus (slow over 2 min)
  • │ (Pre-hospital / no IV access: Buccal Midazolam 10 mg OR Rectal Diazepam 10 mg)
  • │ *If seizures continue after 10 min: repeat IV Lorazepam 4 mg ONCE*
  • │
  • ├── STEP 2 (10–30 min): Established Status — Second-Line IV Antiepileptic Infusion
  • │ (If seizures persist >=10 min after second benzodiazepine dose; infuse over 10–15 min)
  • │ ├── IV Levetiracetam: 60 mg/kg (max 4.5 g) OR
  • │ ├── IV Sodium Valproate: 40 mg/kg (max 3.0 g) OR
  • │ └── IV Phenytoin: 20 mg/kg (max rate 50 mg/min, continuous ECG/BP monitoring)
  • │
  • └── STEP 3 (30–60 min): Refractory Status Epilepticus — General Anaesthesia in ITU
  • ├── Rapid sequence induction and endotracheal intubation
  • ├── IV Anaesthetic agents: Propofol, Midazolam infusion, or Thiopental sodium
  • └── Continuous EEG (cEEG) monitoring targeting electrographic burst suppression
  • 5. UK DVLA Statutory Fitness to Drive Regulations

Compliance with DVLA regulations is mandatory under UK law. Doctors have a professional duty to inform patients of their legal obligation to cease driving and notify the DVLA:

Group 1 Licenses (Cars and Light Motorcycles)

Single Unprovoked Seizure: Must cease driving for a minimum of 6 months . Relicensing may be granted at 6 months if clinical assessment, brain MRI, and EEG demonstrate no significant ongoing epileptogenic risk (risk of recurrence <20% per annum).

Established Epilepsy / Multiple Unprovoked Seizures: Must cease driving for a minimum of 12 continuous months seizure-free.

Established Sleep-Only Seizures: May hold a license if a consistent pattern of seizures occurring exclusively during sleep has been established for at least 1 year without any waking seizures.

Medication Change or Withdrawal: Driving is prohibited during any physician-directed AED dose reduction or medication switch, and for 6 months following the final dose reduction . If a breakthrough seizure occurs due to doctor-supervised reduction, the patient must stop driving for 6 months, provided the previous effective drug regimen is reinstated.

Group 2 Licenses (Buses, Coaches, and Heavy Goods Vehicles / Lorries)

Single Unprovoked Seizure: Must cease driving for a minimum of 5 years . Relicensing requires formal neurological assessment confirming <2% annual recurrence risk.

Established Epilepsy: Must cease driving for a minimum of 10 continuous years completely seizure-free without taking any antiepileptic medications during that entire 10-year period.